The Chemours Company $CC Shares Purchased by Channing Capital Management LLC

Key Points

• Channing Capital Management LLC increased its stake in The Chemours Company by 31.7%, owning approximately 366,345 shares valued at around $4.96 million after purchasing an additional 88,201 shares in Q1.
• Several other institutional investors also expanded their holdings in Chemours, with Vanguard Group increasing its position by 8.3% and Ameriprise Financial adding 23.8% to its stake.
• Ceo Denise Dignam and another insider made recent purchases of Chemours stock, hinting at confidence in the company's prospects despite a recent dividend reduction.

Channing Capital Management LLC grew its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 31.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 366,345 shares of the specialty chemicals company's stock after buying an additional 88,201 shares during the period. Channing Capital Management LLC owned 0.24% of Chemours worth $4,957,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. UMB Bank n.a. lifted its holdings in Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after buying an additional 948 shares in the last quarter. Itau Unibanco Holding S.A. lifted its holdings in Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after buying an additional 1,003 shares in the last quarter. Captrust Financial Advisors lifted its holdings in Chemours by 9.7% in the 4th quarter. Captrust Financial Advisors now owns 13,130 shares of the specialty chemicals company's stock worth $222,000 after buying an additional 1,165 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of Chemours by 6.0% in the 1st quarter. Brown Advisory Inc. now owns 20,874 shares of the specialty chemicals company's stock valued at $282,000 after purchasing an additional 1,174 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Stock Performance

NYSE CC traded down $0.10 on Tuesday, hitting $15.12. The stock had a trading volume of 586,996 shares, compared to its average volume of 3,562,809. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -5.40 and a beta of 1.61. The company's 50-day moving average is $12.99 and its two-hundred day moving average is $12.85.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.62 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the prior year, the firm earned $0.38 EPS. Chemours's quarterly revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, August 15th. Chemours's dividend payout ratio (DPR) is currently -12.50%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. UBS Group cut their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group cut their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Mizuho upped their target price on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Morgan Stanley lowered their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Finally, Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $17.38.

Insider Buying and Selling

In related news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the purchase, the chief executive officer directly owned 191,546 shares of the company's stock, valued at $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Damian Gumpel acquired 13,400 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were bought at an average price of $9.22 per share, for a total transaction of $123,548.00. Following the purchase, the insider directly owned 123,879 shares of the company's stock, valued at approximately $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 25,290 shares of company stock worth $250,437 in the last quarter. Company insiders own 0.34% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.